Tillman U. Gerngross, Ph.D.

Bio

Tillman U. Gerngross, Ph.D. is our co-founder and has served as a member of our board of directors and as our chief executive officer since June 2020. Dr. Gerngross is a founder, director and executive officer of numerous biotechnology companies. He is a co-founder of Adimab, LLC and has served as its chief executive officer and as a director since 2007. He is also a co-founder and chairman of Avitide, Inc. since August 2012, a co-founder and chairman of Alector, Inc. since September 2017, a co-founder, president and chairman of Amagma, Inc. since August 2019 and a co-founder, president and chairman of Ankyra Therapeutics, Inc. since November 2019.

Dr. Gerngross is currently a venture partner at SV Life Sciences Advisors, LLC, which he joined in 2006. Dr. Gerngross co-founded GlycoFi, Inc. and served as its chief scientific officer from 2000 to 2006 until it was acquired by Merck & Company, Inc. Dr. Gerngross currently teaches at the Thayer School of Engineering, at Dartmouth College, where he has taught since 1998. Dr. Gerngross received a B.S. and M.S. in chemical engineering and a Ph.D. in molecular biology from Technical University of Vienna.

Becky Dabora, Ph.D.

Bio

Rebecca Dabora, Ph.D. has served as our chief technology & manufacturing officer since July 2020. In addition, Dr. Dabora is currently serving as principal for RDBio Consulting LLC since July 2005. Prior to joining Adagio, Dr. Dabora served as interim chief technology officer of SwanBio Therapeutics, Inc. from July 2019 to July 2020 and chief technology officer of Aspyrian Therapeutics, Inc. from March 2016 to March 2017. Dr. Dabora received a B.A. in biochemistry from Bowdoin College and a Ph.D. in applied biological sciences and biochemical engineering from the Massachusetts Institute of Technology.

Lynn Connolly, M.D., Ph.D.

Bio

Lynn Connolly, M.D., Ph.D. has served as our chief medical officer since July 2020. Prior to joining Adagio, Dr. Connolly served as senior vice president, clinical research from March 2020 to July 2020 and vice president, clinical research from March 2018 to February 2020 of Vir Biotechnology, Inc. Dr. Connolly served as vice president and head of late development from January 2017 to March 2018 and senior medical director from January 2016 to January 2017 of Achaogen, Inc. Dr. Connolly received a B.A. in molecular biology from University of California, Berkeley and a M.D. and Ph.D. in cell biology from University of California, San Francisco.

Jane Pritchett Henderson

Bio

Jane Pritchett Henderson serves as our chief financial and business officer. In addition, Ms. Henderson has served as a director and chair of the audit committee of Akero Therapeutics, Inc. since April 2019 and IVERIC bio, Inc. since January 2018, and as a director of Ventus since November 2021. Prior to joining Adagio, Ms. Henderson served as chief financial officer of Turnstone Biologics from June 2018 to December 2020, chief financial officer and senior vice president, corporate development of Voyager Therapeutics, Inc. from January 2017 to June 2018 and senior vice president and chief financial & business officer of Kolltan Pharmaceuticals, Inc. from February 2013 to November 2016. Ms. Henderson received a B.S. in psychology from Duke University.

David Hering, M.B.A.

Bio

David Hering, MBA is our interim chief executive officer and chief operating officer. Prior to joining Adagio, Mr. Hering served as the head of the mRNA global franchise business of Pfizer, Inc. from April 2021 to June 2021, the president of North America Vaccines of Pfizer, Inc. from December 2018 to April 2021 and the vaccines commercial officer of Pfizer, Inc. from June 2015 to December 2018. Before joining Pfizer in 2015, Mr. Hering spent seven years at Novartis Vaccines, where he held the position of head of the North America region. Mr. Hering received an MBA from Harvard Business School and a B.S. in operations research and industrial engineering from Cornell University.

Elham (Ellie) Hershberger, Pharm.D.

Bio

Elham (Ellie) Hershberger, Pharm.D. has served as our chief development officer since June 2020. Prior to joining Adagio, Dr. Hershberger served as president of EMH Consulting Group, Inc. from July 2017 to October 2020 and as head of clinical development of Visterra, Inc. from January 2016 to July 2017. Dr. Hershberger received a B.S. in chemistry from University of Minnesota and a Pharm.D. from Ferris State University.

Eric Kimble, M.B.A.

Bio

Eric Kimble, MBA has served as chief commercial officer since September 2020. Prior to joining Adagio, Mr. Kimble served as chief commercial officer for Entasis Therapeutics, Inc. from April 2019 to September 2020 and as a consultant for various emerging biotechnology companies from June 2013 to April 2019. Mr. Kimble received an A.B. in English literature and business economics from Brown University and an MBA from the Harvard Business School.

Laura Walker, Ph.D.

Bio

Laura Walker, Ph.D. is our co-founder and has served as our chief scientific officer since June 2020. In addition, Dr. Walker has served in various roles at Adimab, LLC, including group leader since May 2012, and has served as senior director of antibody sciences since October 2019. Dr. Walker received a B.S. in biochemistry from University of Wisconsin-Madison and a Ph.D. in microbiology and immunology from The Scripps Research Institute.

Jill Andersen, J.D.

Bio

Jill Andersen, J.D. has served as chief legal officer and corporate secretary since November 2021. She joins Adagio from Oyster Point Pharma where she served as general counsel, corporate secretary and chief compliance officer, and recently led and supported critical components of the company’s first FDA approval and product launch. Prior to that, she was with Bristol Myers Squibb, following the Celgene acquisition, and served as vice president, head of legal for the inflammation & immunology global franchise. Prior to joining Celgene, she held positions of increasing responsibility at Novartis, including senior leadership roles in legal and compliance at Novartis Pharmaceuticals Corporation, Novartis Consumer Health and Novartis Services. Ms. Andersen has worked extensively on matters related to product development, marketing approval and commercialization, including product launches across multiple therapeutic areas. Her experience also spans corporate governance, securities, corporate transactions, IP, litigation and investigations. Prior to joining the pharmaceutical industry, she was an Assistant U.S. Attorney for the District of New Jersey and was a litigation associate at the law firm of Davis Polk & Wardwell. She holds a J.D. from Wake Forest University, School of Law and a B.S. in finance from Boston College.

René Russo, Pharm.D.

Bio

René Russo, Pharm.D. is our co-founder and has served as the chair of our board of directors since October 2020. Dr. Russo has served as the chief executive officer of Xilio Therapeutics, Inc since May 2019. Prior to her position at Xilio, Dr. Russo served as president and chief executive officer of Arsanis, Inc. from April 2016 to November 2018, and as its chief development officer from July 2015 to April 2016. In addition, Dr. Russo has served as a director of Celsius Therapeutics, Inc. since May 2020 and X4 Pharmaceuticals, Inc. since March 2019. Dr. Russo received a B.S. in pharmacy and a Pharm.D. from Rutgers University.

Terry McGuire

Bio

Terrance McGuire has served as a member of our board of directors since October 2020. Mr. McGuire has extensive expertise in the biotechnology industry, having spent his career in venture capital and as a director of several biotechnology companies. Mr. McGuire is a founding partner of Polaris Partners, a venture capital firm investing in technology and healthcare companies, since 1996. In addition, Mr. McGuire also currently serves on the boards of directors of Cyclerion Therapeutics since 2019, Seer since 2017, Alector since 2013 , and Adimab, LLC since August 2007. Mr. McGuire received a B.S. in physics and economics from Hobart College, an MBA from Harvard Business School and an M.S. in engineering from the Thayer School at Dartmouth College. 

Ajay Royan

Bio

Ajay Royan has served as a member of our board of directors since October 2020. Mr. Royan has served as managing general partner and founder of Mithril Capital Management LLC, a venture capital firm investing in technology companies, since June 2012 and on the board of directors of several private companies in which Mithril Capital Management LLC or its affiliates have invested. In addition, Mr. Royan has served as a director of Adimab, LLC since September 2014 and has served as a director of Blacksky Holdings, Inc. since June 2016. Mr. Royan serves on the science advisory board of the Oak Ridge National Laboratory, the board of directors of Fulbright Canada, and the Presidents’ Circle of the National Academies of Science, Engineering and Medicine. Mr. Royan received a B.A. from Yale University.

Howard Mayer, M.D.

Bio

Howard Mayer, M.D. has served as a member of our board of directors since August 2020. In addition, Dr. Mayer has served on the board of directors of Entasis Therapeutics Holdings Inc. since August 2019. Dr. Mayer has served as the executive vice president, head of research and development for Ipsen Biopharmaceuticals, Inc. since December 2019. Prior to joining Ipsen, Dr. Mayer served as the senior vice president, chief medical officer and global head of research & development, Neuroscience Division at Shire Pharmaceuticals, Inc. from April 2018 to November 2019 until it was acquired by Takeda Pharmaceutical Company in 2019. Prior to that position, Dr. Mayer served as a senior vice president and head of global research and development at Shire from August 2017 to January 2018, and as a senior vice president and head of global clinical development at Shire from August 2013 to August 2017. Dr. Mayer received a B.A. from the University of Pennsylvania and an M.D. from Albert Einstein College of Medicine.

Anand Shah, M.D.

Bio

Anand Shah, M.D. has served as a member of our board of directors since June 2021. Dr. Shah is currently an Operating Advisor to private equity firm Clayton, Dubilier & Rice and serves as a director of Hero, Big Health, and M2Gen. Dr. Shah served as the deputy commissioner for medical and scientific affairs at the U.S. Food and Drug Administration from January 2020 to January 2021. Dr. Shah previously served as chief medical officer of the Center for Medicare and Medicaid Innovation from October 2017 to January 2019 and senior medical advisor from January 2019 to January 2020, both at the Centers for Medicare and Medicaid Services. Dr. Shah served as an adjunct senior fellow at the Leonard David Institute of Health Economics at the University of Pennsylvania from March 2017 to January 2020. Dr. Shah received an M.D. from the University of Pennsylvania, an M.P.H. in health care management and policy from the Harvard School of Public Health and a B.S. in economics from Duke University.

Tom Heyman

Bio

Tom Heyman has served as a member of our board of directors since June 2021. Mr. Heyman previously served as the president of Johnson & Johnson’s Corporate Venture Capital Group from April 2015 to September 2019 and as the global head of business development for Johnson & Johnson’s Pharmaceutical Group from March 1992 to March 2015. In addition, Mr. Heyman previously served as chief executive officer of Janssen Pharmaceuticals from November 2008 to November 2016. Mr. Heyman has served as a director of OptiNose, Inc. since December 2020 and a director of Akero Therapeutics, Inc. since June 2020. Mr. Heyman received his Master of Laws from Katholieke Universiteit Leuven.

Michael Wyzga

Bio

Michael Wyzga is the president of MSW Consulting, Inc., a private company focused on strategic biotechnology consulting, a position he has held since November 2013. Prior to that, he served as president, chief executive officer and a member of the board of directors of Radius Health, Inc. From 1993 to 2011, Mr. Wyzga served in various senior management positions at Genzyme Corporation, including as executive vice president, finance and as chief financial officer. During his time with Genzyme, Mr. Wyzga played key roles in the successful development and commercialization of a number of important therapies, including Cerezyme for Gauche disease, Fabrazyme for Fabry’s disease, Renagel for use in the treatment of dialysis patients and Campath for chronic lymphocytic leukemia. Mr. Wyzga has served on a number of public company boards, including at Mereo BioPharma Group plc, OncoMed Pharmaceuticals, Inc., X4 Pharmaceuticals, GenSight Biologics, LogicBio Therapeutics, Akebia Therapeutics, Inc., Idenix Pharmaceuticals, Inc., Prosensa Holding B.V. Mr. Wyzga received an MBA from Providence College and a B.S. from Suffolk University.

Redonda Miller, M.D., MBA

Bio

Redonda Miller, M.D., MBA, has served as the president of The Johns Hopkins Hospital since 2016 and has advanced the hospital’s focus on providing exceptional clinical care, enhancing quality, safety and the patient experience, and improving health equity and outcomes for residents in Baltimore City. During her tenure, The Johns Hopkins Hospital has consistently been recognized for extraordinary care, maintaining its rank among the top hospitals in the nation on the U.S. News & World Report Honor Roll and earning its fourth consecutive Magnet designation for nursing excellence. Dr. Miller arrived at Johns Hopkins as a medical student in 1988 and joined the medical faculty in 1997. Since 2004, she has served in several administrative roles of increasing responsibility, including vice chair of clinical operations for the Department of Medicine, vice president of medical affairs for The Johns Hopkins Hospital, and senior vice president of medical affairs for the Johns Hopkins Health System. In 2020, Dr. Miller was inducted into the National Academy of Medicine and the Maryland Chamber of Commerce Business Hall of Fame. She holds an M.D. from Johns Hopkins University School of Medicine, an MBA from Johns Hopkins Carey Business School and a B.S. in biology from The Ohio State University.

Ellen Marram, MBA

Bio

Ellen Marram, MBA, recently retired as the lead director for Eli Lilly and Ford Motor Company and previously served as the presiding director of The New York Times. She was the CEO of the Tropicana Beverage Group and the Nabisco Biscuit Company and, as a managing director or advisor to several private equity firms, primarily focused on health-related consumer brands and served on many private company boards. She is currently the chair of Newman’s Own Inc, the food company which gives all profits to philanthropic causes and serves as a director of the Newman’s Own Foundation. She also serves on a number of health-related and other non-profit boards. Ms. Marram holds an MBA from Harvard Business School and a B.A. from Wellesley College where she serves as a trustee.